Pattern of Dyslipidemias, Associated Atherogenic Risk and Insulin Sensitivity in Type 2 Diabetes Mellitus

Authors

Keywords:

Atherogenic indices, Dyslipidemias, HbA1C, HOMA-IR, Insulin resistance, QUICKI

Abstract

Dyslipidemia is a major phenotype associated with diabetes mellitus, and this is essential in the development of cardiovascular risk. This study aimed to establish the most common dyslipidemia pattern among type 2 DM, atherogenicity, and associated insulin sensitivity. A cross-sectional study, involving 141 type 2 diabetes patients and 140 healthy individuals as controls, was adopted. A multistage sampling technique was employed, and a semi-structured interviewer-administered questionnaire was used to collect socio-demographic and clinical data. The combined dyslipidemia pattern had the highest percentage among subjects, with a value of 52(45.6%) observed. It was followed by mixed dyslipidemias with a value of 50(43.9%). A higher percentage of increased risk of CVD was found among the subjects for CRI-I (74; 52%), CRI-II (73; 51.8%), and AC (75; 53.2%) compared with control CRI-I (15; 10.7%), CRI-II (7; 5.0%) and AC (15; 10.7%), p-values <0.001. A greater percentage of subjects demonstrated insulin resistance, as indicated by HOMA-IR (79, 56.0%) and QUICKI (64, 45.4%), compared to the controls with p <0.001. HbA1C correlated with HOMA-IR (r=0.235, p=0.005) and QUICKI (r=-0.196, p=0.020). Mixed dyslipidemias (elevated total cholesterol, elevated LDL-C and low HDL-C) as the highest form of dyslipidemia pattern was observed. CRI-I, CRI-II and AC were better predictors of CVD than an ordinary lipid profile. HOMA-IR and QUICKI were better tools for assessment of insulin sensitivity/resistance than plasma glucose and insulin. HbA1c can therefore be adopted as a screening tool for insulin resistance in a large population, not as a diagnostic tool alone.

Author Biographies

  • Akande JO, Ladoke Akintola University of Technology

    Department of Chemical Pathology, Ladoke Akintola University of Technology, Ogbomoso.

  • Akande Roseline O, Ladoke Akintola University of Technology

    epartment of Community Medicine, Ladoke Akintola University of Technology, Ogbomoso. 

  • Olufemi-Aworinde KJ, Ladoke Akintola University of Technology

    Department of Haematology and Blood Transfusion, Ladoke Akintola University of Technology, Ogbomoso

  • Idowu OJ, Bowen University

    Department of Medical Science, Bowen University, Iwo.

  • Atiba AS, Ekiti State University

    Department of Chemical Pathology, Ekiti State University, Ado-Ekiti.

  • Akande-Richard O, Ladoke Akintola University of Technology

    Department of Medicine and Surgery, College of Health Sciences, LAUTECH, Ogbomoso

References

1. Azeez, TA, Adio M, Bamidele OT. Lipid Profiles of Nigerians Living with type 2 Diabetes Mellitus : A Systematic Review and Meta-Analysis. J Diabetes Endocr Pr. 2022; 4:160–64.

2. Ugwu CE, Ezeanyika LU, Daikwo MA, Amana R. Lipid Profile of A Population of Diabetic Patients attending Nigerian National Petroleum Corporation Clinic, Abuja. Adv. J. Microbiol. Res. 2017: 2017.

3. Shiferaw B, Tagesch Y, Abdurehman EM. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities , and People’s Region. Diabetes, Metab. Syndr. Obes. Targets Ther. 2017;10:265–271.

4. Kane JP, Pullinger CR., Goldfine ID, Malloy MJ. Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. Curr. Opin. Pharmacol. 2021; 61:21–27.

5. Parcero-valdés JJ. Diabetic dyslipidemia. Cardiovasc Metab Sci. 2021 32, 168–172.

6. Kassahun H, Abebe T. Dyslipidemia and Its Associated Risk Factors Among Adult Type-2 Diabetic Patients at Jimma University Medical Center , Jimma, Southwest Ethiopia. Diabetes, Metab. Syndr. Obes. Targets Ther. 2020; 13:4589–4597.

7. Jisieike-Onuigbo NN, Unuigbe EI, Oguejiofor CO. Dyslipidemias in type 2 diabetes mellitus patients in Nnewi South-East Nigeria. Ann. Afr. Med. 2011; 10:285–289.

8. Wusu AD, Yusuf AA, Kazeem I. Dyslipidemia Profile Of Type 2 Diabetic Patients Attending State Hospital In Ilaro, Nigeria. UNILAG J. Med. 2016;4:28–38.

9. Warraich HJ, Rana JS. Dyslipidemia in diabetes mellitus and cardiovascular disease. Cardiovasc. Endocrinol 2017;6:27–32.

10. Mehta RK, Koirala P, Mallick RL, Parajuli S, Jha R. Dyslipidemia in Patients with Type 2 Diabetes Mellitus in a Tertiary Care Centre: A Descriptive Cross-sectional Study. J Nepal Med Assoc. 2021;59:305–309.

11. Sultana M, Akhter Y, Parvin M, Naznin L, Mmu A, Ma W. Plasma Atherogenic Index in Type 2 Diabetes Mellitus Patients 1. 204 JAFMC Bangladesh. 2019; 15: 204–205.

12. Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A. Characterization of lipid parameters in diabetes mellitus - A Nigerian report. Int. Arch. Med.2009; 2: 1–7.

13. Park SY, Gautier J, Chon S. Assessment of Insulin Secretion and Insulin Resistance in Human. Diabetes Metab J. 2021; 45: 641–654.

14. Dutta S, Bhatt S. Evaluation of Serum Insulin Level as a Marker of Insulin Resistance in Obese with and without Diabetes Type-2. J Heal. Med Res. 2019; 1: 12–16.

15. Agu P, Egbugara MN, Ogboi JS, Ajah LO, Nwagha UI, Ugwu EO, Ezugwu EC. Atherogenic Index, Cardiovascular Risk Ratio, and Atherogenic Coefficient as Risk Factors for Cardiovascular Disease in Pre‑eclampsia in Southeast Nigeria: A Cross‑Sectional Study. Niger. J. Clin. Pract. 2024; 27: 221–227.

16. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi SR. Int J Pharm Bio Sci. 2013;3: 359–364.

17. Sasikala T, Goswami K. Castelli risk index-1 and atherogenic coefficient are better predictors of cardiometabolic risk in patients with hypothyroidism. Int J Clin Biochem Res. 2020; 7: 254–259.

18. Raaj I, Thalamati MN, Rao A. The Role of the Atherogenic Index of Plasma and the Castelli Risk Index I and II in Cardiovascular Disease. Cureus. 2024; 16: 1–12.

19. Singh M, Pathak MS, Paul A. A Study on Atherogenic Indices of Pregnancy-Induced Hypertension Patients as Compared to Normal Pregnant Women. J. Clin. Diagnostic Res. 2015; 9: 5–8.

20. Wu L, Parhofer KG. Diabetic dyslipidemia. M E T A Boli Sm C L Ini C A L E X P Eri M E N T A L. 2014; 63: 1469–1479.

21. Yanai H, Hirowatari Y, Yoshida H. Diabetic Dyslipidemia: Evaluation and Mechanism. Glob. Heal. Med. 2019; 1: 30–35.

22. Stein E, Harvey K, Samuel G, Bonita F. Plasma Lipid Concentrations in Non-Diabetic, African American Adults. Metabolism. 2007; 56: 954–960.

23. Sophia S, Yu B, Castillo DC, Courville AB, Sumner AE. The triglyceride paradox in people of African descent. Metab. Syndr. Relat. Disord. 2012; 10: 77–82.

24. Sumner AE, Gloria LV, David JG, Karl BF, Richard NB, Boston RC. Normal triglyceride levels despite insulin resistance in African Americans: role of lipoprotein lipase. Metabolism. 2005; 7: 902–909.

25. Goedecke JH. Expanding Our Understanding of the Triglyceride Paradox in Populations of African Ancestry. Circ. Res. 2020; 126: 109–111.

26. Anne ES, Karl BF, Genovese DJ, Criqui MH. Fasting Triglyceride and the Triglyceride–HDL Cholesterol Ratio Are Not Markers of Insulin Resistance in African Americans. Arch. Intern. Med. 2005; 165: 1395–400.

27. Emili N, Jesudasan J, Alwar V, Pushparaj L, Karunakaran B, Rajappa T, et al. Correlation of Atherogenic Index of Plasma and Castelli Risk Indices with HbA1c In Type 2 Diabetes Mellitus Patients. Int. J. Med. Public Heal. 2025; 15: 1308–1312.

28. Afeikhena EO, Oyakhire FO, Gabriel BI, Esezobor IK, Efenarhua S, Odionyenma

UC, et al. Evaluation and correlation of lipid profile variations with atherogenic index

in Type II diabetic patients in. J. Med. Lab. Diagn. 2025; 14: 1–7.

29. Baral S, Hamal AB, Shyam K, Gupta S. Assessment of lipid abnormalities and cardiovascular risk indices in type 2 diabetes mellitus.2019; 10: 39–44.

30. Cheneke W, Suleman S, Yemane T, Abebe G. Assessment of glycemic control using glycated hemoglobin among diabetic patients in Jimma University specialized hospital. BMC Res. Notes. 2016; 9: 1–10.

31. Akinloye O, Adaramoye O, Akinlade KS, Odetola A, Raji A. Relationship between Fasting Plasma Glucose and Glycated Haemoglobin In Adult Diabetic Nigerians. African J. Biomed. Res. 2007; 10: 127–132.

32. Zhou L, Luo Y, Wang Y, Cheng Y. The clinical implications of fasting serum insulin levels in patients with insulin-treated type 2 diabetes: a cross-sectional survey. Clin. Diabetes Heal. 2023; 4: 1–11.

33. Veeradej P, Katherine HI, Maria FLD, Julian MA, Garvey WT. Limitations in the Use of Indices Using Glucose and Insulin Levels to Predict Insulin Sensitivity. Diabetes Care 2013; 36: 845–853.

34. Geloneze B, Carolina A, Vasques J, Camargo CF, Pareja JC, RosadomDL, et al. HOMA1-

IR and HOMA2-IR indexes in identifying insulin resistance and metabolic

syndrome – Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab. 2009; 53: 281–287.

35. Józef D, Agata D. Could glycated hemoglobin be used as a diagnostic tool in diabetes mellitus? Polish Arch. Intern. Med. 2010; 120: 109–14.

36. Jaja MA, Mkpe A, Amadi SC, Kasso T, Allison T, Oloyede OA. et al. Glycosylated Haemoglobin (HbA1c ) as a Diagnostic Criterion for Hyperglycaemia First Detected in Pregnancy. Niger Med J. 2023; 64: 281–292.

37. Lee J, Kim M, Jang JY, Oh CM. Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non ‑ diabetic adults: a KoGES prospective cohort study. Clin. Diabetes Endocrinol. 2023; 9: 1–8.

Downloads

Published

2025-09-22

Issue

Vol. 6 No. 3 (2025): Assessment of the usefulness of maternal serum beta-human chorionic gonadotrophin as predictive marker for pre eclampsia and poor clinical neonatal outcome

Section

Articles